Martin Sos
Affiliations: | 2011-2015 | Cellular and Molecular Pharmacology | University of California, San Francisco, San Francisco, CA |
Google:
"Martin Sos"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Müller N, Lorenz C, Ostendorp J, et al. (2023) Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer. Cancer Research |
| Riedel R, Fassunke J, Tumbrink HL, et al. (2022) Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. European Journal of Cancer (Oxford, England : 1990). 179: 124-135 |
| Lategahn J, Tumbrink HL, Schultz-Fademrecht C, et al. (2022) Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry |
| Werr L, Plenker D, Dammert MA, et al. (2022) CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Molecular Cancer Therapeutics |
| Schaufler D, Ast DF, Tumbrink HL, et al. (2021) Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology. 5: 102 |
| Brägelmann J, Lorenz C, Borchmann S, et al. (2021) MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications. 12: 5505 |
| Bebber CM, Thomas ES, Stroh J, et al. (2021) Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nature Communications. 12: 2048 |
| Tumbrink HL, Heimsoeth A, Sos ML. (2020) The next tier of EGFR resistance mutations in lung cancer. Oncogene |
| Nogova L, Mattonet C, Scheffler M, et al. (2020) Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Medicine |
| Michels S, Heydt C, van Veggel B, et al. (2019) Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Jco Precision Oncology. 3 |